Revenue
2020
2021
2022
2023
2024
2025
Biofrontera Inc. (BFRI)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $41.7M | $37.3M | $34.1M | $28.7M | $24.1M | $18.8M |
| Research & development | $3.7M | $2.1M | $77,000 | — | — | — |
| Operating expenses | $53.1M | $54.5M | $56.7M | $47.3M | $49.3M | $28.5M |
| Operating income | −$11.3M | −$17.2M | −$22.7M | −$18.6M | −$25.2M | −$9.6M |
| EBITDAderived | −$11.2M | −$16.8M | −$22.1M | −$18.1M | −$24.7M | −$9.0M |
| Net income | −$10.5M | −$17.8M | −$20.1M | −$640,000 | −$37.7M | −$11.0M |
| Basic EPSper diluted share | -$1.04 | -$3.22 | -$13.02 | -$0.61 | -$4.28 | -$479.48 |
| Diluted EPSper diluted share | -$1.04 | -$3.22 | -$13.02 | -$0.61 | -$4.28 | -$479.48 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Sep 16, 2025Form 4 | Biofrontera AGDirector,TenPercentOwner | BuySeries D Convertible Preferred Stock · derivative | 3.0K | — | — | 3.0K |